Federal Register / Vol. 66, No. 111 / Friday, June 8, 2001 / Notices 30935

TIMES AND DATES: 9 a.m.–6 p.m., June 13,

2001. 9 a.m.–4 p.m., June 14, 2001.

PLACE: The Old Courthouse on the

Square, 101 East Court Square, Decatur,

Georgia 30030, telephone (404) 373–

1088.

STATUS: Open to the public, limited only

by the space available. The meeting

room accommodates approximately 50

people.

PURPOSE: The mission of the Task Force

is to develop and publish a Guide to

Community Preventive Services, which

is based on the best available scientific

evidence and current expertise

regarding essential public health

services and what works in the delivery

of those services.

MATTERS TO BE DISCUSSED: Agenda items

include: presentation of

recommendations for approval for the

following chapters: Cancer, Physical

Activity, Tobacco, Vaccine Preventive

Diseases and Violence Prevention;

presentation of the dissemination plan;

and general updates on Methods and the

Clinical Guide.

Agenda items are subject to change as

priorities dictate.

CONTACT PERSON FOR ADDITIONAL

INFORMATION: Stephanie Zaza, M.D.,

M.P.H., Chief, Community Guide

Branch, Division of Prevention Research

and Analytic Methods, Epidemiology

Program Office, CDC, 4770 Buford

Highway, M/S K–73, Atlanta, Georgia

30341, telephone 770/488–8189.

Persons interested in reserving a space

for this meeting should call 770/488–

8189 by close of business on June 11,

2001.

The Director, Management Analysis

and Services office has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: June 4, 2001.

John Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention.

[FR Doc. 01–14448 Filed 6–7–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Submission for OMB review; Comment

request

Title: Voluntary Surveys of Program

Partners to Implement Executive Order.

OMB No.: 0980–0266.

Description: Description: Under the

provisions of the Federal Paperwork

Reduction Act of 1995 (Pub. L. 104–13),

the Administration for Children and

Families (ACF) is requesting clearance

for instruments to implement Executive

Order 12862 within the ACF. The

purpose of the data collection is to

obtain customer satisfaction information

from those entities who are funded to be

our partners in the delivery of services

to the American public. ACF partners

are those entities that receive funding to

deliver services or assistance from ACF

programs. Examples of partners are

States and local governments,

territories, service providers, Indian

Tribal organizations, grantees,

researchers, or other intermediaries

serving target populations identified by

and funded directly or indirectly by

ACF. The surveys will obtain

information about how well ACF is

meeting the needs or our partners in

operating the ACF programs.

Respondents: State, Local, Tribal

Governments or Not-for Profit

institutions.

ANNUAL BURDEN ESTIMATES

Instrument Number of

respondents

Number of

responses

per respondent

Average

burden

hours per

response

Total burden hours

In-depth Interview ............................................................................................................ 476 3.16 .33 496

Estimated Total Annual Burden Hours ............................................................................ .................... .................... .................... 496

Additional Informqation: Copies of

the proposed collection may be obtained

by writing to The Administration for

Children and Families, Office of

Information Services, 370 L’Enfant

Promenade, SW., Washington, DC

20447, Attn: ACF Reports Clearance

Officer.

OMB Comment: OMB is required to

make a decision concerning the

collection of information between 30

and 60 days after publication of this

document in the Federal Register.

Therefore, a comment is best assured of

having its full effect if OMB receives it

within 30 days of publication. Written

comments and recommendations for the

proposed information collection should

be sent directly to the following:

Office of Management and Budget,

Paperwork Reduction Project, 725 17th

Street, NW., Washington, DC 20503,

Attn: Desk Officer for ACE.

Dated: June 1, 2001.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 01–14456 Filed 6–7–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Endocrinologic and Metabolic Drugs

Advisory Committe; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Endocrinologic

and Metabolic Drugs Advisory

Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on July 26 and 27, 2001, 8 a.m. to

5 p.m.

Location: Holiday Inn, Versailles

Ballrooms, 8120 Wisconsin Ave.,

Bethesda, MD.

Contact: Kathleen Reedy or LaNise

Giles, Center for Drug Evaluation and

Research (HFD–21), Food and Drug

30936 Federal Register / Vol. 66, No. 111 / Friday, June 8, 2001 / Notices

Administration, 5600 Fishers Lane (for

express delivery, 5630 Fishers Lane, rm.

1093), Rockville, MD 20857, 301–827–

7001, FAX 301–827–6776, or e-mail:

reedyk@cder.fda.gov, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), code 12536.

Please call the Information Line for upto-date information on this meeting.

Agenda: On July 26, 2001, the

committee will discuss new drug

application (NDA) 21–332, SymlinTM

(pramlintide acetate, Amylin

Pharmaceuticals, Inc.) as an adjunctive

therapy to insulin to improve glycemic

and metabolic control in patients with

type 1 or type 2 diabetes mellitus alone

or in combination with oral

hypoglycemic agents. On July 27, 2001,

the committee will discuss NDA 21–

318, Forte ́oTM (teriparatide injection,

rDNA origin, Eli Lilly and Co.) for the

treatment of osteoporosis in men and in

postmenopausal women.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by July 20, 2001. Oral

presentations from the public will be

scheduled between approximately 11

a.m. and 11:30 a.m. each day. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before July 20, 2001, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

requested to make their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: May 31, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–14410 Filed 6–7–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Care Financing Administration

[HCFA–1194–N]

Medicare Program; Meeting of the

Practicing Physicians Advisory

Council on June 25, 2001

AGENCY: Health Care Financing

Administration (HCFA), HHS.

ACTION: Notice of meeting.

SUMMARY: In accordance with section

10(a) of the Federal Advisory Committee

Act, this notice announces a meeting of

the Practicing Physicians Advisory

Council. This meeting is open to the

public.

DATES: The meeting is scheduled for

June 25, 2001, from 8:30 a.m. until 5

p.m., e.d.t.

ADDRESSES: The meeting will be held in

Room 505A, 5th Floor, Hubert H.

Humphrey, 200 Independence Avenue,

SW., Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Paul

Rudolf, M.D., J.D., Executive Director,

Practicing Physicians Advisory Council,

Room 435–H, Hubert H. Humphrey

Building, 200 Independence Avenue,

SW., Washington, DC 20201, (202) 690–

7874. News media representatives

should contact the HCFA Press Office,

(202) 690–6145. Please refer to the

HCFA Advisory Committees

Information Line (1–877–449–5659 toll

free)/(410 786–9379 local) or the

internet (http://www.hcfa.gov/fac) for

additional information and updates on

committee activities.

SUPPLEMENTARY INFORMATION: The

Secretary of the Department of Health

and Human Services (the Secretary) is

mandated by section 1868 of the Social

Security Act to appoint a Practicing

Physicians Advisory Council (the

Council) based on nominations

submitted by medical organizations

representing physicians. The Council

meets quarterly to discuss certain

proposed changes in regulations and

carrier manual instructions related to

physicians’ services, as identified by the

Secretary. To the extent feasible and

consistent with statutory deadlines, the

consultation must occur before

publication of the proposed changes.

The Council submits an annual report

on its recommendations to the Secretary

and the Administrator of the Health

Care Financing Administration not later

than December 31 of each year.

The Council consists of 15 physicians,

each of whom has submitted at least 250

claims for physicians’ services under

Medicare or Medicaid in the previous

year. Members of the Council include

both participating and nonparticipating

physicians, and physicians practicing in

rural and underserved urban areas. At

least 11 members must be doctors of

medicine or osteopathy authorized to

practice medicine and surgery by the

States in which they practice. Members

have been invited to serve for

overlapping 4-year terms. In accordance

with section 14 of the Federal Advisory

Committee Act, this Council

automatically terminates two years after

its date of establishment, unless the

Council is renewed before the

termination date by appropriate agency

action. Therefore, terms of more than

two years for members are contingent

upon the renewal.

The Council held its first meeting on

May 11, 1992.

The current members are: Jerold M.

Aronson, M.D.; Richard Bronfman,

D.P.M.; Joseph Heyman, M.D.; Sandral

Hullett, M.D.; Stephen A. Imbeau, M.D.;

Angelyn L. Moultrie, D.O.; Derrick K.

Latos, M.D. (pending re-appointment);

Dale Lervick, O.D.; Sandra B. Reed,

M.D.; Amilu Rothhammer, M.D.; Victor

Vela, M.D.; and Kenneth M. Viste, Jr.,

M.D.; and Douglas L. Wood, M.D. The

Council chairperson is pending

selection.

The agenda will provide for

discussion and comment on the

following topics:

• Inputs and insights on the draft

instructions to implement Advance

Beneficiary Notices.

• Physician Regulatory Issues Team

(PRIT) update.

• Evaluation and Management

Documentation Guidelines (update and

discussion on medical review form).

• Physician Participation in

Evaluation and Management Guidelines

Pilot Studies (How to address issues of

miscoding and medical review in the

studies).

• Contractor Oversight Issues

(provider education, customer service,

medical review, and contractor

performance evaluation).

For additional information and

clarification on the topics listed, call the

contact person in the FOR FURTHER

INFORMATION CONTACT section of this

notice.

Individual physicians or medical

organizations that represent physicians

and who wish to be scheduled to make

5-minute oral presentations on agenda

issues should contact the Executive

Director by 12 noon, June 15, 2001.

Testimony is limited to the listed

agenda issues only. The number of oral

presentations may be limited by the

time available. A written copy of the

presenter’s oral remarks should be

submitted to the Executive Director no

later than 12 noon, June 18, 2001, for

distribution to Council members for

review prior to the meeting. Physicians

and organizations not scheduled to

speak may also submit written

comments to the Executive Director and

Council members. The meeting is open

to the public, but attendance is limited

to the space available. Individuals

requiring sign language interpretation

for the hearing impaired or other special

accommodation should contact John